Preventing Metabolic Diseases

The Silent Spectrum Nobody Talks About

In the UK, around 5 million people have type 2 diabetes. Another 13 million are estimated to have pre-diabetes. And behind both of those numbers sits a much larger group — people with insulin resistance that isn't yet severe enough to register on standard tests, driving low-grade metabolic dysfunction that's already raising their risk of cardiovascular disease, fatty liver, dementia, and cancer. The total proportion of UK adults with some degree of metabolic impairment is estimated by some researchers at close to half the population. Most of them don't know it. Most of them would pass a standard NHS health check.

That's the uncomfortable truth about metabolic disease: it is not a switch that flips. It is a slow drift along a spectrum, and by the time the standard markers — fasting glucose, HbA1c — flag a problem, the process has typically been running for a decade or more. Understanding that spectrum, and where you sit on it, is one of the most practically valuable things anyone in midlife can do.

Metabolic Health

It's a Slow Slide, Not a Sudden Drop — and You Can Reverse Direction

Most people think metabolic disease arrives as a diagnosis. It doesn't. It builds quietly over years — and the window to reverse it is widest long before any doctor flags a problem. Understanding where you are on the spectrum is the first step.

The Metabolic Decline Spectrum

Healthy metabolic function

Blood sugar stable, insulin working efficiently, energy levels consistent, no excess visceral fat. The body processes meals and stores energy without strain. This is the starting point — and the goal.

Early insulin resistance — no symptoms, normal blood sugar

Cells start to respond less efficiently to insulin. The pancreas compensates by producing more. Blood sugar stays normal — so this stage is invisible on standard tests. Fasting insulin is the only blood test that catches it. Lifestyle changes here are highly effective and fully reversible.

↩ Most reversible stage. Exercise and reducing refined carbohydrates often restore normal function within weeks.

Pre-diabetes — blood sugar elevated but below the diabetes threshold

The pancreas can no longer fully compensate. Blood sugar after meals rises higher and stays elevated longer. Fat accumulates in the liver and around organs. Around 1 in 3 UK adults are pre-diabetic — most have no idea. NHS screening begins to flag this via HbA1c. Still reversible with sustained lifestyle change.

↩ Still reversible. Weight loss of 5–10% body weight, combined with aerobic exercise, reduces progression to type 2 by over 50% in trials.

Type 2 diabetes — pancreatic capacity significantly impaired

Blood sugar is persistently elevated even fasting. The NHS will now diagnose and treat this. Medication is often necessary. Remission is still possible — particularly in the early years after diagnosis — through significant caloric restriction or low-carbohydrate diets, but it requires more intensive intervention than earlier stages.

↩ Remission possible, especially early. The DiRECT trial showed ~50% of participants achieved remission through structured weight loss — but the window narrows over time.

Complications — cardiovascular, kidney, nerve and eye damage

Chronically elevated blood sugar damages blood vessels and nerves throughout the body. This is the stage that causes heart attacks, kidney failure, blindness and amputations. These complications develop over years, not overnight. Every earlier stage is an opportunity to prevent reaching this one.

The Four Highest-Leverage Interventions

Exercise — especially after meals

Muscle contraction pulls glucose out of the bloodstream independently of insulin. A 10-minute walk after eating reduces blood sugar spikes by up to 30%. Resistance training builds the metabolic sink — more muscle means more glucose storage capacity.

Cut ultra-processed food, not just sugar

Ultra-processed foods drive insulin resistance through multiple pathways — refined carbohydrates, seed oils, disrupted gut microbiome, and hyperpalatable combinations that override satiety signals. Whole food doesn't need to be low-carb to be effective — processing matters as much as macros.

Reduce visceral fat

Fat stored around the organs — not under the skin — drives insulin resistance, inflammation and liver disease. Waist circumference is a better proxy for this than BMI. A waist above 88cm for women or 102cm for men warrants action regardless of overall weight.

Prioritise sleep

A single night of poor sleep measurably reduces insulin sensitivity the next day. Chronic sleep deprivation drives cortisol elevation, increases hunger hormones and promotes fat storage — all independently of diet. You cannot fully out-exercise or out-diet chronic sleep debt.

💡 You don't have to be overweight to have metabolic disease. "TOFI" — thin outside, fat inside — describes people with normal weight but significant visceral fat and insulin resistance. Waist circumference, fasting insulin and energy patterns are more informative than the scales.

How insulin resistance develops — and why it matters beyond diabetes

Insulin is the hormone that allows glucose to enter cells and be used for energy. When cells are repeatedly exposed to high levels of insulin — driven by frequent glucose spikes from refined carbohydrates, sedentary behaviour, poor sleep, and chronic stress — they gradually become less responsive to it. The pancreas compensates by producing more. For a while, blood glucose stays normal. But fasting insulin rises, and that elevated insulin is itself harmful — promoting fat storage (particularly visceral fat), driving inflammation, raising triglycerides, lowering HDL cholesterol, and accelerating the growth of certain cancer cells.

This is the central problem of insulin resistance: it causes significant metabolic damage long before glucose levels become abnormal. A person can have fasting glucose of 5.2 mmol/L — entirely normal — and simultaneously have fasting insulin three to four times higher than optimal, indicating that their pancreas is working extremely hard to maintain that normal reading. The glucose looks fine. The system underneath is under significant strain. HOMA-IR — calculated from fasting glucose and fasting insulin — captures this strain in a way that glucose alone cannot.

Visceral fat: the metabolic driver most tests miss

Not all fat is metabolically equal. Visceral fat — the fat stored around the liver, pancreas, and other abdominal organs — is far more biologically active than subcutaneous fat (the fat under the skin). It releases free fatty acids directly into the portal circulation, impairs insulin signalling in the liver, promotes systemic inflammation through adipokine secretion, and drives fatty liver disease. A person can have a normal BMI and carry a significant burden of visceral fat — a pattern researchers call TOFI: thin outside, fat inside. This is not rare. Studies using DEXA scanning and MRI have found visceral fat accumulation in substantial proportions of people with healthy BMIs, particularly those who are sedentary.

Waist circumference is a reasonable proxy for visceral fat in the absence of a DEXA scan. A waist above 94cm for men or 80cm for women signals elevated metabolic risk regardless of weight. But it's a blunt tool. Two people with identical waist measurements can have very different visceral fat burdens depending on where their fat is distributed. A DEXA scan provides a direct measurement and is available privately for around £100–150.

Non-alcoholic fatty liver disease — the condition most people haven't heard of

NAFLD — non-alcoholic fatty liver disease — now affects an estimated one in three adults in Western countries, making it the most common liver condition in the world. It develops when excess fat accumulates in liver cells, typically as a consequence of insulin resistance and high fructose intake. In most people it causes no symptoms. Liver function tests — the standard blood panel — are often normal in early NAFLD. It is typically found incidentally on an ultrasound done for another reason.

NAFLD exists on its own spectrum. In its early stages, it is largely reversible with lifestyle change. In a smaller proportion of people it progresses to NASH — non-alcoholic steatohepatitis — an inflammatory form that can advance to cirrhosis and liver failure. The key driver of progression is continued insulin resistance and metabolic dysfunction. Treating NAFLD is, in most cases, not a liver problem requiring a liver treatment — it is a metabolic problem requiring metabolic intervention. Reducing refined carbohydrates and fructose, losing visceral fat, and increasing physical activity are the primary tools. There are currently no approved pharmaceutical treatments for NAFLD in the UK, though several are in late-stage trials.

What exercise does to metabolic health — specifically

Skeletal muscle is the largest glucose disposal organ in the body. When muscle contracts during exercise, it can take up glucose independently of insulin — through a separate transporter pathway involving GLUT4. This means that exercise directly bypasses the insulin resistance problem, allowing glucose clearance even when insulin signalling is impaired. The effect is acute — lasting for hours after a session — and chronic: regular training increases the number and sensitivity of GLUT4 transporters in muscle over time, improving insulin sensitivity durably.

Resistance training is particularly effective for metabolic health because it builds muscle mass, and more muscle means a larger glucose reservoir. A single resistance training session can lower blood glucose for up to 24 hours in people with insulin resistance. Combined with aerobic exercise — which improves mitochondrial function and fat oxidation — the metabolic effect of a consistent training programme is comparable in magnitude to first-line pharmaceutical interventions for pre-diabetes, without any of the side effects.

Sleep, stress, and the hormonal dimension

Two levers that rarely feature in metabolic health conversations are sleep and cortisol. A single night of poor sleep measurably impairs insulin sensitivity — multiple controlled studies have demonstrated this. The mechanism involves elevated cortisol and growth hormone disruption, both of which promote glucose release from the liver and reduce glucose uptake in peripheral tissues. Chronic sleep deprivation drives persistent insulin resistance through sustained disruption of these pathways. People who sleep fewer than six hours consistently have substantially higher rates of type 2 diabetes than those sleeping seven to eight hours, even after controlling for diet and exercise.

Chronic stress elevates cortisol, which raises blood glucose by stimulating hepatic glucose production — a mechanism designed for short-term emergencies that becomes harmful when chronically activated. It also drives visceral fat accumulation directly. Cortisol promotes fat storage in abdominal depots through glucocorticoid receptor activation in adipose tissue. This is why people under sustained occupational or emotional stress often gain abdominal weight even without eating more — a genuinely counterintuitive finding that the research supports clearly.

'Insulin resistance doesn't announce itself. It quietly reshapes your metabolic landscape for years before any standard test picks it up — which is exactly why the right test, at the right time, matters so much.'

GLP-1 medications and where they fit

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide — have transformed the treatment landscape for metabolic disease in the past three years. They reduce appetite, slow gastric emptying, improve insulin secretion, and in large trials have produced weight loss of 15–20% of body weight — far beyond what previous medications achieved. The SURMOUNT and SELECT trials have also shown significant reductions in cardiovascular events and mortality, extending their clinical value well beyond weight loss alone.

They are not, however, a replacement for lifestyle change. The metabolic benefits of GLP-1 agonists are substantially augmented by exercise and diet — and muscle loss during rapid weight loss on these medications is a real concern that makes resistance training during treatment particularly important. They are also not yet available to most people through the NHS outside specific criteria, and private access is expensive. For those who qualify and choose to use them, they represent a genuinely significant tool. For everyone else, the lifestyle interventions described on this page remain the primary means of reversing insulin resistance and preventing progression along the metabolic spectrum.

The practical starting point

If you take one thing from this page: fasting glucose alone is not an adequate measure of metabolic health. Ask for fasting insulin alongside it. Calculate or ask your GP to calculate HOMA-IR. Measure your waist circumference. If you're concerned, consider a DEXA scan. These four data points — fasting insulin, HOMA-IR, waist circumference, and visceral fat — give you a far more accurate picture of where you sit on the metabolic spectrum than any standard health check.

Then act on what you find. Reduce refined carbohydrates and fructose. Prioritise sleep as a metabolic intervention, not a lifestyle preference. Build and maintain muscle. Keep moving throughout the day — prolonged sitting independently impairs glucose metabolism even in people who exercise regularly. And if visceral fat is elevated, treat its reduction as a priority rather than an aesthetic concern. The downstream consequences are significant enough to warrant it.